Clinical Trial Update: A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies [Phase 1]

View source ↗

Summary

MacroGenics reports a Phase 1 study of MGD024 in relapsed or refractory hematologic malignancies is currently recruiting across multiple disease types. The tria…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Aggressive Systemic Mastocytosis
• B-cell Leukemia
• Blastic Plasmacytoid Dendritic Cell Neoplasm
• Chronic Myeloid Leukemia
• Classical Hodgkin Lymphoma
• Hairy Cell Leukemia
• Myelodysplastic Syndromes

Drugs mentioned

• MGD024

Snippet

Sponsor: MacroGenics | Conditions: Leukemia, Acute Myeloid, Myelodysplastic Syndromes | Phase 1 | Status: RECRUITING